Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Abstract

mortality rates (HR=1.55, 95% CI 1.04-2.30, p=0.03) compared to the "average weight" BMI group. Interestingly, overweight and obese class I but not Obese class II and III patients showed statistically significant earlier engraftment in the form of documented increase of absolute neutrophilic count (ANC) to 500/mL (P value 0.01 and < 0.0001 respectively). Conclusions: BMI 35 is a risk factor for increased mortality after allogenic HSCT after accounting for impacts of comorbidities. Pre-transplant weight reduction to a goal of BMI <35 whenever possible may be a reasonable strategy to improve survival and lower the likelihood to develop Cgvhd after allogenic HSCT, although this approach needs to be studied in a clinical trial. There is a rationale to consider T cell depletion for patients with pre-transplant BMI 35.